Finance

Lists
1177:HKG
Sino Biopharmaceutical Ltd
5,25 HKD
-0,38%
(-0,020) 1D
16-окт., 16:08:14 GMT+8  ·   HKD
All symbols
SymbolPriceChange% Change
Generating top insights for 1177...
Open
5,40 HKD
High
5,50 HKD
Low
5,14 HKD
Mkt. cap
98,09 млд
Avg. vol.
69,33 млн
Volume
83,88 млн
Dividend
2,29%
Quarterly dividend
0,03 HKD
Ex-dividend date
2025-ж., 29-авг.
P/E ratio
33,86
52-wk high
7,79 HKD
52-wk low
4,19 HKD
EPS
0,16 HKD
Shares outstanding
12,64 млд
No. of employees
23 миң
Open
5,40 HKD
High
5,50 HKD
Low
5,14 HKD
Mkt. cap
98,09 млд
Avg. vol.
69,33 млн
Volume
83,88 млн
Dividend
2,29%
Quarterly dividend
0,03 HKD
Ex-dividend date
2025-ж., 29-авг.
P/E ratio
33,86
52-wk high
7,79 HKD
52-wk low
4,19 HKD
EPS
0,16 HKD
Shares outstanding
12,64 млд
No. of employees
23 миң
News stories
From web sources and news partners
Profile
Sino Biopharmaceutical Limited, shortly SBP Group, is a pharmaceutical conglomerate in China. The Company was listed on the Hong Kong Stock Exchange in 2000 and included in 2013 as a constituent stock of MSCI Global Standard Indices – MSCI China Index, Hang Seng Index in 2018, Hang Seng China Enterprises Index in 2019, and Hang Seng Connect Biotech 50 Index and Hang Seng China 25 Index in 2020. The Group’s principal subsidiaries include: Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Beijing Tide Pharmaceutical Co. Ltd., Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd., Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd., Jiangsu Chia Tai Qingjiang Pharmaceutical Co., Ltd. and invoX Pharma Limited. Its products including biopharmaceutical and chemical medicines are used in a host of therapeutic areas, such as tumors, liver diseases, respiratory system diseases and surgery/analgesia. Wikipedia
About Sino Biopharmaceutical Ltd
CEOLi Yi
Employees22,8 миң
Founded2000
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
7,13 млд
7,13 млд
9,72 млд
9,72 млд
Cost of goods sold
1,31 млд
1,31 млд
1,65 млд
1,65 млд
Cost of revenue
1,31 млд
1,31 млд
1,65 млд
1,65 млд
Research and development expenses
2,93 млд
2,93 млд
1,54 млд
1,54 млд
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2,80 млд
2,80 млд
3,11 млд
3,11 млд
Operating expense
4,38 млд
4,38 млд
4,77 млд
4,77 млд
Total operating expenses
5,69 млд
5,69 млд
6,42 млд
6,42 млд
Operating income
1,44 млд
1,44 млд
3,31 млд
3,31 млд
Other non operating income
97,99 млн
97,99 млн
76,64 млн
76,64 млн
EBT including unusual items
488,22 млн
488,22 млн
3,67 млд
3,67 млд
EBT excluding unusual items
1,55 млд
1,55 млд
3,56 млд
3,56 млд
Income tax expense
323,77 млн
323,77 млн
597,96 млн
597,96 млн
Effective tax rate
66,32%
66,32%
16,29%
16,29%
Other operating expenses
-1,35 млд
-1,35 млд
113,21 млн
113,21 млн
Net income
-522,62 млн
-522,62 млн
1,72 млд
1,72 млд
Net profit margin
-7,33%
-7,33%
17,66%
17,66%
Earnings per share
-
-
-
-
Interest and investment income
196,36 млн
196,36 млн
250,06 млн
250,06 млн
Interest expense
-77,56 млн
-77,56 млн
-84,75 млн
-84,75 млн
Net interest expenses
118,80 млн
118,80 млн
165,31 млн
165,31 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
1,66 млд
1,66 млд
3,57 млд
3,57 млд
Gain or loss from assets sale
-5,58 млн
-5,58 млн
-
-
AI content may include mistakes. Learn more
Google колдонмолору